Mutations or deletions in the CDKN2A gene can lead to the loss of p16ink4a function. Without the inhibitory action of p16ink4a, CDK4/6 can phosphorylate RB1, allowing the cell cycle to progress unchecked. This loss of regulation is a common event in various types of cancers, including melanoma, pancreatic cancer, and certain types of gliomas.
